Abstract
The reaction of cyanoacetylhydrazine (1) with 3-(2-bromoacetyl)-2H-chromen-2-one (2) in 1,4-dioxan gave the hydrazidehydrazone derivative (3). The latter compound was cyclized to the 1,3,4-oxadiazine derivative 4, its 4-bromo derivative underwent a series of cross coupling reactions together with [4+2] cycloaddition reactions with either acrylonitrile or ethyl acrylate to afford the pyran derivatives 10a and 10b, respectively. The antitumor evaluation of the newly synthesized products against three cancer cell lines, namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268) were recorded. Four of the synthesized compounds namely 7c, 10a, 11a and 12b showed high inhibitory effects. Moreover, the anti-leishmanial activity of the newly synthesized product was tested on Leishmania donovani amastigotes showed that some compounds have high activity.
Keywords: Cross coupling, Hydrazide-hydrazone, 1, 3, 4-oxadiazine, coumarin, Anti-tumor.
Current Organic Chemistry
Title:Design, Synthesis and Molecular Modeling Studies of Some Heterocyclic Compounds Derived from the Suzuki-coupling of 6-bromo-1,3,4-oxadiazine Together with their Antitumor and Anti-leishmanial Evaluations
Volume: 17 Issue: 17
Author(s): Rafat M. Mohareb, Sherif M. Sherif and Adel Abou Elkair
Affiliation:
Keywords: Cross coupling, Hydrazide-hydrazone, 1, 3, 4-oxadiazine, coumarin, Anti-tumor.
Abstract: The reaction of cyanoacetylhydrazine (1) with 3-(2-bromoacetyl)-2H-chromen-2-one (2) in 1,4-dioxan gave the hydrazidehydrazone derivative (3). The latter compound was cyclized to the 1,3,4-oxadiazine derivative 4, its 4-bromo derivative underwent a series of cross coupling reactions together with [4+2] cycloaddition reactions with either acrylonitrile or ethyl acrylate to afford the pyran derivatives 10a and 10b, respectively. The antitumor evaluation of the newly synthesized products against three cancer cell lines, namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268) were recorded. Four of the synthesized compounds namely 7c, 10a, 11a and 12b showed high inhibitory effects. Moreover, the anti-leishmanial activity of the newly synthesized product was tested on Leishmania donovani amastigotes showed that some compounds have high activity.
Export Options
About this article
Cite this article as:
Mohareb M. Rafat, Sherif M. Sherif and Elkair Abou Adel, Design, Synthesis and Molecular Modeling Studies of Some Heterocyclic Compounds Derived from the Suzuki-coupling of 6-bromo-1,3,4-oxadiazine Together with their Antitumor and Anti-leishmanial Evaluations, Current Organic Chemistry 2013; 17 (17) . https://dx.doi.org/10.2174/13852728113179990037
DOI https://dx.doi.org/10.2174/13852728113179990037 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014
Current Drug Targets Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions
Current Medicinal Chemistry Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology Gene Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Safety Profile of Plasmid/Liposomes and Virus Vectors in Clinical Gene Therapy
Current Drug Safety The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Isoform-Selective PI3K Inhibitors for Various Diseases
Current Topics in Medicinal Chemistry The Genetic Regulation of ADPRT/PARP-1 in Aging and Cancer Susceptibility
Current Pharmacogenomics The Medicinal Potential of Natural Products for the Development of Anti- Influenza Agents
Current Drug Targets Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Multidrug Resistance Associated Proteins as Determining Factors of Pharmacokinetics and Pharmacodynamics of Drugs
Current Drug Metabolism Entropy and Enthalpy in the Activity of Tubulin-Based Antimitotic Agents
Current Chemical Biology Micelle-based Systems for Pulmonary Drug Delivery and Targeting
Drug Delivery Letters Beneficial Effects of Bioactive Phospholipids: Genomic Bases
Current Nutrition & Food Science Comparison of High-Density Short Oligonucleotide Microarray Platforms
Current Bioinformatics The Intriguing Interplay Between Therapies Targeting the Epidermal Growth Factor Receptor, the Hypoxic Microenvironment and Hypoxia-inducible Factors
Current Pharmaceutical Design Engineered Magnetic Core-Shell Structures
Current Pharmaceutical Design Subject Index to Volume 10
Protein & Peptide Letters